Navigation Links
OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer
Date:5/30/2009

including the risk that the survival benefit will not be confirmed by a Phase 3 clinical trial, risks associated with obtaining funding from third parties or completing a financing necessary to support the costs and expenses of a Phase 3 clinical trial, the timing and costs of clinical trials and regulatory approvals will be different than management currently anticipates, risks relating to the development, safety and efficacy of therapeutic drugs and potential applications for these products and the risk factors set forth in the Company's filings with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for fiscal year 2008. The Company undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof.


'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
2. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
3. OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
4. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
5. OncoGenex Reports First Quarter Financial Results
6. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
7. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
8. OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
9. OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
10. OncoGenex Pharmaceuticals to Webcast Financial Results for Fourth Quarter and Fiscal Year 2008 and Provide Outlook for 2009
11. OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... December 23, 2014 GMO corn cases ... company, Syngenta, are in the process of being consolidated ... consolidated case is In Re: Syngenta AG MIR 162 ... Court for the District of Kansas. , Management of ... handed over to U.S. District Judge John W. Lungstrum.* ...
(Date:12/24/2014)... York (PRWEB) December 23, 2014 According to ... Long Island Affiliate of ITRA Global, the national office market ... steady recovery. This is evidenced by the third quarter’s ... stock market. Low energy costs have held inflation down ... only negative is the housing market remaining soft. , This ...
(Date:12/24/2014)... Diego, CA (PRWEB) December 23, 2014 ... where their Twitter followers can submit their #HolidayInTheLab ... themselves and their lab mates. , For those struggling ... lab mates, the Pipette.com Holiday in the Lab Contest ... Pipette.com Twitter followers to send pictures of ...
(Date:12/24/2014)... LOUIS , Dec. 23, 2014 ... today that the waiting period under the Hart-Scott-Rodino ... the acquisition expired on December 22, 2014, thereby ... review requirement for the acquisition of the Company ... U.S. antitrust clearance satisfies another condition to closing ...
Breaking Biology Technology:Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3
... A. Knapp, 1, 2 E. Lehmann, 2 L. Hennes, 3 , ... , 1 Department of Biological Anthropology, University of Cambridge,U.K. ... of Wisconsin, , , ... Wisconsin Hospital and Clinics, Madison, Wisconsin, U.S.A. , ...
... , , Menu B. Leddy, Biotechnology Research Department,Orange ... , ... characterization of bacterial species from membrane , ... of bacterial cells from membrane biofilms cannot ...
... of Medical Microbiology and Hygiene,University of Regensburg, 93053 Regensburg, Germany , ... Abstract , Serodiagnosis of ... on the detection of antibodies to distinct EBV antigens. In the past few ... serodiagnostic assay systems , have been considerably ...
Cached Biology Technology:Separation of HLA-DRB Alleles by Denaturing Gradient Gel Electrophoresis using the DCode System 2Separation of HLA-DRB Alleles by Denaturing Gradient Gel Electrophoresis using the DCode System 3Separation of HLA-DRB Alleles by Denaturing Gradient Gel Electrophoresis using the DCode System 4Separation of 16S rRNA PCR Products From a Model Community Using Temporal Temperature Gradient Gel Electrophoresis, Rev A 2Separation of 16S rRNA PCR Products From a Model Community Using Temporal Temperature Gradient Gel Electrophoresis, Rev A 3Separation of 16S rRNA PCR Products From a Model Community Using Temporal Temperature Gradient Gel Electrophoresis, Rev A 4Separation of 16S rRNA PCR Products From a Model Community Using Temporal Temperature Gradient Gel Electrophoresis, Rev A 5Separation of 16S rRNA PCR Products From a Model Community Using Temporal Temperature Gradient Gel Electrophoresis, Rev A 6Separation of 16S rRNA PCR Products From a Model Community Using Temporal Temperature Gradient Gel Electrophoresis, Rev A 7Preparative SDS-PAGE Electrophoresis of a Recombinant Epstein-Barr Virus Encoded Protein and Its Application in Serodiagnostic Test Systems, Rev C 2Preparative SDS-PAGE Electrophoresis of a Recombinant Epstein-Barr Virus Encoded Protein and Its Application in Serodiagnostic Test Systems, Rev C 3Preparative SDS-PAGE Electrophoresis of a Recombinant Epstein-Barr Virus Encoded Protein and Its Application in Serodiagnostic Test Systems, Rev C 4Preparative SDS-PAGE Electrophoresis of a Recombinant Epstein-Barr Virus Encoded Protein and Its Application in Serodiagnostic Test Systems, Rev C 5Preparative SDS-PAGE Electrophoresis of a Recombinant Epstein-Barr Virus Encoded Protein and Its Application in Serodiagnostic Test Systems, Rev C 6Preparative SDS-PAGE Electrophoresis of a Recombinant Epstein-Barr Virus Encoded Protein and Its Application in Serodiagnostic Test Systems, Rev C 7Preparative SDS-PAGE Electrophoresis of a Recombinant Epstein-Barr Virus Encoded Protein and Its Application in Serodiagnostic Test Systems, Rev C 8
(Date:12/17/2014)... 2014 Valencell, a leader in performance biometric ... to industry leaders such as Intel, Jabra, Atlas, and ... wearable products. These products will be showcased at CES ... Vegas . "Our partners choose ... robust – with the clinical data to back it ...
(Date:12/15/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/87pph8/global_facial ) ... Facial Recognition Market 2015-2019" report to their ... Facial recognition is a technology used ... measures the overall facial feature of a person ... distance between eyes. Facial recognition is used for ...
(Date:12/11/2014)... SALEM, N.C. , Dec. 10, 2014  That blood ... for quite a while. Hypertension – the medical term for ... in the early 1800s, and the inflatable cuff that,s used ... That doesn,t, however, mean there,s nothing new about hypertension, its ... some long-held beliefs about the condition and the best ways ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4
... professor Karen Warkentin, working at the Smithsonian Tropical ... frog embryos at a very early developmental stage ... reported in the Nov. 7, 2008 issue of ... initial responses to the environment may be critical ...
... West Nile virus in North America over the past decade ... according to an article in the November issue of ... before its emergence in New York in 1999, has since ... Nile virus has killed hundreds of millions of birds and ...
... -- Scientists have long known that it,s possible for one ... by skipping or including certain sequences from the messenger RNA. ... as alternative splicing, is both far more prevalent and varies ... all human genes, about 94 percent, generate more than one ...
Cached Biology News:Red-eyed treefrog embryos actively avoid asphyxiation inside their eggs 2Human genes sing different tunes in different tissues 2
... assay can detect H2O2 or peroxidase activity ... oxidizes ADHP in a 1:1 stoichiometry to ... 530-571 nm, emission at 590-600 nm). This ... one-step, homogeneous, no wash assay system. ADHP ...
...
Rabbit polyclonal to Staphylococcus Enterotoxin A (HRP) ( Abpromise for all tested applications)....
... net results - with a modular approach ... management! The ChemStation Plus NDS family provides ... acquisition and data management, giving you the ... your labs needs now and that can ...
Biology Products: